CRMD
Strong BuyUnloved QualityAI neutralCorMedix Inc. · Healthcare · United States · $599M cap · $6.9M/day traded
$7.46 +1.1% · close 12 Oct · scored 14 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Report expected 16 Nov: the next-year EPS estimate has been little changed over the last 13 weeks.
As of 14 Oct 2026, MoatMap's StockRank for CorMedix Inc. (CRMD) is 98/100, ranked against 24,000+ stocks in 35 markets (Quality 82, Value 86, Momentum 44, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
CorMedix has achieved meaningful commercialization with its DefenCath catheter lock solution, supporting high profitability and asset turnover scores. However, technical price action has lagged broader sector benchmarks despite the presence of an active share repurchase program. Additional commercial traction and share price stabilization are needed to clarify the medium-term path.
ABOUT CORMEDIX INC.
Read
CorMedix Inc. is a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases, particularly catheter-related infections. Its lead product candidate, DefenCath, aims to provide a novel antimicrobial solution for hemodialysis catheters, positioning the company to address a significant unmet medical need upon regulatory approval.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.4K | 0 | 43.5M | 311.7M | 1582.8% | 462.2M | 337.1M | 289.3M | -3.7% |
| EPS | -0.74 | -0.91 | -0.30 | 2.25 | — | 2.05 | — | — | — |
| Shares | 42.8M | 54.9M | 64.4M | 79.3M | +85.1% | 77.9M | — | — | — |
| Debt | 0.8M | 0.7M | 0.5M | 148.9M | 470.4% | 147.5M | — | — | — |
| Equity | 55.1M | 70.1M | 84.7M | 405.3M | 94.5% | — | — | — | — |
| Op CF | -24.4M | -38.4M | -50.6M | 175.0M | — | 253.9M | — | — | — |
| Inv CF | -3.7M | -17.1M | 21.2M | -308.4M | — | — | — | — | — |
| Fin CF | 17.9M | 55.9M | 26.3M | 238.5M | — | — | — | — | — |
No new 52-week low for 30 weeks, 22% above that low, but not back above a rising 50-day average.
Swung more than 76% of stocks we rank over the past year (61% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CRMD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CRMD | CorMedix Inc.(you) | $599M | 98 | Strong Buy |
| PBYI | Puma Biotechnology, Inc. | $479M | 98 | Strong Buy |
| ZVRA | Zevra Therapeutics, Inc. | $672M | 92 | Strong Buy |
| RIGL | Rigel Pharmaceuticals, Inc. | $899M | 98 | Strong Buy |
| 1521.HK | Frontage Holdings Corporation | $280M | 95 | Strong Buy |
| PLX | Protalix BioTherapeutics, Inc. | $226M | 99 | Strong Buy |
| INVA | Innoviva, Inc. | $1.5B | 93 | Strong Buy |
| QTTB | Q32 Bio Inc. | $285M | 88 | Strong Buy |
| MDXG | MiMedx Group, Inc. | $696M | 74 | Buy |
| ABUS | Arbutus Biopharma Corporation | $961M | 81 | Strong Buy |
Peer medians: ROE -26.1% · P/E 29.0x · Gross margin 64.2%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.